Charles Schwab
YARW

Charles Schwab’s Yarrow Bioscience YARW Stock Holding History

Charles Schwab’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22
Closed -$71K – 3546
2021
Q2 		$71K Sell
22
-88
-80% -$348K ﹤0.01% 3326
2021
Q1 		$678K Buy
110
+11
+11% +$79.8K ﹤0.01% 2978
2020
Q4 		$565K Hold
99
– – ﹤0.01% 2945
2020
Q3 		$594K Buy
99
+20
+25% +$117K ﹤0.01% 2830
2020
Q2 		$495K Buy
79
+52
+193% +$352K ﹤0.01% 2832
2020
Q1 		$262K Buy
27
+18
+200% +$282K ﹤0.01% 2930
2019
Q4 		$150K Hold
9
– – ﹤0.01% 3071
2019
Q3 		$145K Sell
9
-6
-40% -$96.8K ﹤0.01% 3076
2019
Q2 		$321K Buy
15
+4
+36% +$99K ﹤0.01% 2987
2019
Q1 		$322K Hold
11
– – ﹤0.01% 2924
2018
Q4 		$158K Hold
11
– – ﹤0.01% 3045
2018
Q3 		$385K Buy
11
+4
+57% +$123K ﹤0.01% 2922
2018
Q2 		$202K Sell
7
-1
-13% -$38.9K ﹤0.01% 3060
2018
Q1 		$1.08M Buy
+8
New +$973K ﹤0.01% 2491

Other funds holding YARW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab's YARW Position: Q3 2021 in Review

Charles Schwab sold out of Yarrow Bioscience (YARW) in Q3 2021, closing a stake of 22 shares — an estimated $71K sold.

Charles Schwab first reported a position in YARW in Q1 2018 and held it in 14 quarters. The position peaked at $1.08M in Q1 2018. 58 funds tracked by Wall St. Rank hold YARW as of Q3 2021.

  • Charles Schwab reported no remaining Yarrow Bioscience position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 22 Yarrow Bioscience shares in Q3 2021, an estimated $71K.
  • Charles Schwab first reported a position in Yarrow Bioscience in Q1 2018 and held it in 14 quarters.
  • Charles Schwab's Yarrow Bioscience position peaked at $1.08M in Q1 2018.
  • 58 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.